AR127055A1 - Sales agonistas de sstr4 - Google Patents
Sales agonistas de sstr4Info
- Publication number
- AR127055A1 AR127055A1 ARP220102484A ARP220102484A AR127055A1 AR 127055 A1 AR127055 A1 AR 127055A1 AR P220102484 A ARP220102484 A AR P220102484A AR P220102484 A ARP220102484 A AR P220102484A AR 127055 A1 AR127055 A1 AR 127055A1
- Authority
- AR
- Argentina
- Prior art keywords
- salts
- formula
- compound
- compound according
- treatment
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 5
- 102100023801 Somatostatin receptor type 4 Human genes 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 108010064556 somatostatin receptor subtype-4 Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 208000002193 Pain Diseases 0.000 abstract 2
- -1 3-methyl-2-pyridyl Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a sales específicas de (1S,5R)-(1a,5a,6a)-N-[1,1-dimetil-2-[(3-metil-2-piridil)oxi]etil]-3-azabiciclo[3.1.0]hexano-6-carboxamida, a composiciones farmacéuticas que comprenden dichas sales, a métodos de uso de dichas sales para tratar trastornos fisiológicos, y a intermedios útiles en la síntesis de las sales. Reivindicación 1: Un compuesto de la fórmula (1), o un hidrato de este. Reivindicación 4: El compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 3, que es: de fórmula (2). Reivindicación 7: Un compuesto de la fórmula (3). Reivindicación 9: Un compuesto de la fórmula (4). Reivindicación 21: Un compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 13 para su uso en el tratamiento del dolor. Reivindicación 23: Un compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 13 para su uso en el tratamiento del dolor neuropático. Reivindicación 25: Un compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 13 para su uso en el tratamiento del dolor asociado con la osteoartritis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163243785P | 2021-09-14 | 2021-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127055A1 true AR127055A1 (es) | 2023-12-13 |
Family
ID=83508479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102484A AR127055A1 (es) | 2021-09-14 | 2022-09-13 | Sales agonistas de sstr4 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11834435B2 (es) |
| AR (1) | AR127055A1 (es) |
| AU (1) | AU2022348561A1 (es) |
| CA (1) | CA3231451A1 (es) |
| CO (1) | CO2024003038A2 (es) |
| TW (2) | TW202400577A (es) |
| WO (1) | WO2023044326A1 (es) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159941A (en) | 1996-05-14 | 2000-12-12 | Novo Nordisk A/S | Use of somatostatin agonists and antagonists for treating diseases related to the eye |
| US6355613B1 (en) | 1996-07-31 | 2002-03-12 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
| US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
| US6063796A (en) | 1997-04-04 | 2000-05-16 | Merck & Co., Inc. | Somatostatin agonists |
| HU230612B1 (hu) | 2002-11-27 | 2017-04-28 | Incyte Corporation | Kemokin receptorokat módosító hatású 3-aminopirrolidin-származékok |
| FI20031454A0 (fi) | 2003-10-06 | 2003-10-06 | Juvantia Pharma Ltd Oy | Selektiivisiä somatostatiinireseptori 1 ja/tai 4 -agonisteja ja -antagonisteja |
| US20100004339A1 (en) | 2003-10-06 | 2010-01-07 | Oy Juvantia Pharma Ltd. | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists |
| UA86037C2 (ru) | 2003-10-14 | 2009-03-25 | Пфайзер Продактс Инк. | Бициклические [3.1.0] производные, как ингибиторы переносчика глицина |
| WO2007029086A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors |
| GB0616574D0 (en) * | 2006-08-21 | 2006-09-27 | Glaxo Group Ltd | Compounds |
| EP2129660A2 (en) | 2006-12-19 | 2009-12-09 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| MX2011000051A (es) | 2008-07-07 | 2011-07-28 | Fasgen Inc | Nuevos compuestos, composiciones farmaceuticas que contienen los mismos, metodos para usar los mismos, y metodos para preparar los mismos. |
| WO2010059922A1 (en) | 2008-11-21 | 2010-05-27 | Ligand Pharmaceuticals Incorporated | Pyrrolidine carboxamide compounds |
| US8835472B2 (en) | 2010-09-02 | 2014-09-16 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| BR112013007566A2 (pt) | 2010-09-28 | 2016-08-02 | Panacea Biotec Ltd | novos compostos bicíclicos |
| EP2685828A4 (en) | 2011-03-17 | 2014-08-13 | Merck Sharp & Dohme | SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS |
| CN102675290B (zh) | 2011-03-18 | 2014-11-12 | 山东亨利医药科技有限责任公司 | 含有并环的二氢吡唑类化合物 |
| KR101556318B1 (ko) | 2013-05-15 | 2015-10-01 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체 |
| US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
| EA032104B1 (ru) | 2014-11-14 | 2019-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) |
| EP3218371B1 (en) | 2014-11-14 | 2018-09-26 | Boehringer Ingelheim International GmbH | Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (sstr4) agonists |
-
2022
- 2022-09-13 TW TW112136333A patent/TW202400577A/zh unknown
- 2022-09-13 TW TW111134517A patent/TWI822326B/zh active
- 2022-09-13 AR ARP220102484A patent/AR127055A1/es unknown
- 2022-09-14 US US17/944,429 patent/US11834435B2/en active Active
- 2022-09-14 WO PCT/US2022/076401 patent/WO2023044326A1/en active Application Filing
- 2022-09-14 AU AU2022348561A patent/AU2022348561A1/en active Pending
- 2022-09-14 CA CA3231451A patent/CA3231451A1/en active Pending
-
2023
- 2023-08-07 US US18/366,218 patent/US20240067628A1/en active Pending
-
2024
- 2024-03-13 CO CONC2024/0003038A patent/CO2024003038A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11834435B2 (en) | 2023-12-05 |
| US20240067628A1 (en) | 2024-02-29 |
| CO2024003038A2 (es) | 2024-04-18 |
| TW202400577A (zh) | 2024-01-01 |
| TW202330492A (zh) | 2023-08-01 |
| AU2022348561A1 (en) | 2024-03-14 |
| WO2023044326A1 (en) | 2023-03-23 |
| US20230099116A1 (en) | 2023-03-30 |
| CA3231451A1 (en) | 2023-03-23 |
| TWI822326B (zh) | 2023-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116753A1 (es) | Proceso de preparación de un derivado de pirazolsulfonilamida | |
| EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| AR048973A1 (es) | (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas | |
| AR057874A1 (es) | Aminopirimidinas utiles como inhibidores de quinasa | |
| BRPI0409624A (pt) | 2-hidróxi-3-diaminoalcanos de benzamida | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| PE20140966A1 (es) | Quinazolincarboxamida azetidinas | |
| AR043823A1 (es) | Compuestos derivados de oxima, su preparacion y elaboracion de medicamentos que los contienen | |
| CO2023000396A2 (es) | Nuevo inhibidor de la secreción de ácido y uso del mismo | |
| NO20064982L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| BR112023006312A2 (pt) | Composto, métodos para preparar o composto, composição farmacêutica e uso do composto | |
| CO2022015930A2 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
| AR121483A1 (es) | Hidrato cristalino de un compuesto inhibidor de jak | |
| CA2064592A1 (fr) | Derives d'amino-acides, leur procede de preparation et leur application therapeutique | |
| AR046705A1 (es) | Pirido-7-pirimidin-7-onas substituidas con hidroxialquilo | |
| CO2022015927A2 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso | |
| CO2022008690A2 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| AR127055A1 (es) | Sales agonistas de sstr4 | |
| BR0311801A (pt) | Composição de imidazol, método para produção do mesmo, composição farmacêutica, embalagem comercial, método para a profilaxia ou tratamento de doenças, método para erradicar helicobacter pylori de um animal infectado com helicobacter pylori, e, uso de um composto | |
| CU20200102A7 (es) | Compuestos derivados de isoindolin-1,2,4-triazol-3-carbonitrilo útiles para el tratamiento de enfermedades cinetoplastídicas | |
| BR112023001145A2 (pt) | Composto tendo atividade inibitória de quinase | |
| CO2023009368A2 (es) | Cocristal de un inhibidor de cdk |